Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Verrica Pharmaceuticals Discloses Last Patient Dosed In Part 2 Of Phase 2 Study Of VP-315, A Potential First-in-Class Oncolytic Peptide-Based Immunotherapy, For Treatment Of Basal Cell Carcinoma

Author: Benzinga Newsdesk | January 05, 2024 08:32am

Posted In: VRCA